Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuojin Wan + Vonoprazan for GERD with Depression
NCT06481787Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
Randomised trial of zuojin wan in gastroesophageal reflux disease (GERD) and major depressive disorder (MDD) (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: Reflux Disease Questionnaire at 8 weeks, Hamilton Depression Scale at 8 weeks and 1 more. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
zuojin wan
03
Conditions
gastroesophageal reflux disease (GERD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06481787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481787.